

Key to Diagnostic Excellence

in partnership with Lancet Laboratories South Africa

MEDICAL LABORATORY REPORT

ISO/IEC 15189:2012 ACCREDITED LABORATORY

Patient :
MICHAEL OJ SAMPSON

Doctors Ref
NOT AVAILABLE

Lab Ref : Page : 2
706168418 / 23/11/17 0703

BIOCHEMISTRY

Test	Result	Reference
LIVER FUNCTION TESTS (CONT.)		
> S-g-GLUTAMYL TRANSFERASE	23 IU/L	< 55
> S-ALT (GPT)	34 IU/L	0 - 41
> S-AST (GOT)	37 IU/L	0 - 40
> S-TOTAL PROTEIN	62 g/L	L 64 - 83
> S-ALBUMIN	41 g/L	39.7 - 49.5
> S-CKMB quantitative	5.1 ng/ml	0 - 6.73
Please note new reference range		
> S-CHOLESTEROL	7.1 mmol/L	H < 5.2
> S-LDL CHOLESTEROL	4.8 mmol/L	H < 3.0
> S-HDL CHOLESTEROL	2.0 mmol/L	> 1.45
> S-NON HDL CHOLESTEROL	5.1 mmol/L	H < 3.8
Non-HDL cholesterol is a secondary target for lipid lowering therapy in patients with fasting serum triglycerides > 2.26 mmol/L after achieving the LDL-cholesterol target, however triglyceride levels greater than 5.7 mmol/L should be treated first to prevent pancreatitis.		
The target for non-HDL cholesterol in persons with elevated fasting triglycerides is 0.8 mmol/L HIGHER than their LDL cholesterol target.		
> S-CHOL./HDL RATIO	3.6	< 4.1
> S-TRIGLYCERIDE	0.71 mmol/L	< 1.70
> COMMENT		

TREATMENT TARGETS FOR EACH RISK GROUP AS DEFINED BY FRAMINGHAM RISK SCORING SYSTEM(FRS)

:	:	TOTAL	:	LDL-C	:	Non HDL-C	:	ApoB	
:	RISK (FRS)	:	CHOLESTEROL	:	mmol/L	:	mmol/L	:	g/L
:	:	:	(mmol/L)	:	:	:	:	:	:
:	** Very	:	:	:	:	:	:	:	:
:	High	:	< 4.0	:	< 1.8	:	< 2.6	:	< 0.8
:	:	:	:	:	:	:	:	:	:
:	High	:	< 4.5	:	< 2.5	:	< 3.3	:	< 1.0
:	:	:	:	:	:	:	:	:	:
:	Moderate/	:	< 5.0	:	< 3.0	:	< 3.8	:	_____
:	Low	:	:	:	:	:	:	:	_____

** Very high risk subjects are:

- 1) Established atherosclerotic disease,
- 2) Type 2 DM
- 3) Type 1 DM with micro-albuminuria and proteinuria